- Admin
- #1
A COVID-19 vaccine candidate from China's Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus as a booster dose than Sinovac's shot, clinical trial data showed. The result for Walvax's ARCoV candidate, which is yet to be peer reviewed, comes as competition for the COVID booster market intensifies in China, where more than half of the 1.4 billion population have so far received a non-mRNA booster shot. Among 300 healthy adults vaccinated with two doses of either a Sinovac or Sinopharm vaccine around six months earlier, the neutralising antibody level against Omicron in those given an ARCoV booster was 4.4-fold higher than in those who received a Sinovac third dose, researchers said in a paper published on Tuesday.